Search
for
Sort by
Research 421–450 of 920
- Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
- Hypertrichosis of the malar areas and poliosis of the eyelashes caused by latanoprost
- 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
- The Role of Patients in Alopecia Areata Endpoint Development: Understanding Physical Signs and Symptoms
- “Miliacin encapsulated by polar lipids stimulates cell proliferation in hair bulb and improves telogen effluvium in women”
- Management of Toxicities of Targeted Therapies
- A New Clinical Variant of Hereditary Localized Alopecia: Report of a Chinese Family Mapped to Chromosome 2p25.1–2p23.2
- Hair transplantation. 3rd ed.
- 40062 Mini pulse corticosteroid therapy with oral dexamethasone for moderate to severe alopecia areata: a multicentric study
- Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
- Is There a Role for Radiofrequency Devices in Hair?
- Frontal Fibrosing Alopecia
- FUE Hair Transplantation
- Answer
- Hypertrichosis of the malar areas and poliosis of the eyelashes caused by latanoprost
- Recent Progress in Prostaglandin F 2a Ethanolamide (Prostamide F2a) Research and Therapeutics
- Comparative Effectiveness and Safety of Baricitinib and Ritlecitinib in Severe Alopecia Areata: A Real-World Monocentric Retrospective Study
- Trichotillomania Mimicking Alopecia Areata in an Adolescent Girl: A Clinicopathologic Case Report
- BH21 Efficacy and safety of oral Janus kinase inhibitors in the treatment of alopecia areata: a systematic review and meta-analysis
- The potential of dihydroquercetin and other active substances in cosmetic products for regulating hair follicle activity in the periorbital region: a review
- Real‐World Efficacy and Safety of Tofacitinib for Patients With Alopecia Areata: A Retrospective Multi‐Center Cohort Study
- The most impactful aspects of living with alopecia areata among patients commencing systemic treatments: Evaluating patients’ perspectives to guide therapy
- The pharmacovigilance analysis of adverse events of erlotinib based on the open access FAERS database
- Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata
- Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
- Baricitinib Effectiveness and Patient Impressions in Routine Clinical Practice: 12-month Results from a Prospective Observational Real-world Study
- Long‐Term Real‐World Outcomes of Baricitinib in Severe Alopecia Areata: A 104‐Week Retrospective Analysis From a Single Institute
- Erlotinib-induced trichomegaly of eyelashes in lung cancer treatment: Epidermal growth factor receptor inhibitor side effect
- Baricitinib regrows hair in adolescents with alopecia areata
- [[Translated article]]Low-dose oral minoxidil for frontal fibrosing alopecia: a 122-patient case series